Amryt Pharma, a biopharmaceutical company, agreed to acquire Chiasma, a biopharmaceutical company, for $330m. The transaction is supported by Athyrium Capital Management, Highbridge Capital Management and MPM Capital. Amryt shareholders will own approximately 60% of Amryt post transaction and Chiasma shareholders will own approximately 40% of Amryt post transaction. "This deal further solidifies our position as a global leader in treating rare and orphan conditions. The combined business will have three approved commercial products and an exciting pipeline of development assets. We see significant revenue growth opportunities for MYCAPSSA in acromegaly and are also very excited to further develop the potential for MYCAPSSA. Our combined pipeline will have four product candidates in late clinical stages," Joe Wiley, Amryt CEO.